Therapeutic Immunology

Therapeutic Immunology discusses evolving and established modalities of treatment in both immunologic and systemic diseases. It will be organized by modality (drugs, biologics, maneuvers) and by point of intervention rather than disease, and explain how and why these interventions work in these particular disorders and at various stages on the pathophysiologic process. The authors are considered to be among the ablest people in modern immunology and their support team is equally as impressive. Using a clinical versus theoretical approach, the chapter will be organized similarly as follows: introduction, history of the agent, structure, molecular and cellular basis of action, diseases in which this approach is useful,

Table of Contents:
Part 1:Introduction:; 1. The Immune System; 2. Endothelial Cells in Immune Inflammation; Part 2: Drugs:; A) Antimetabolites and Radiomimetics: 3. Cyclophosphamide; 4. The Purine Antagonists: Azathioprine and Mycophenolate; 5. Methotrexate; 6. Progress in Therapeutic Immunosuppression: CsA, Tacrolimus (FK 506), and Rapamycin; B) Corticosteroids: 7. Glucocoricoid Hormone Action; 8. Immunosuppressive and Anti-Inflammatory Actions of Corticosteroids; C) Anti-inflammatory Agents: 9. Cyclooxygenase Inhibitors; 10. Receptor Site Blockers; 11. 5-Lipoxygenase Inhibitors; 12. Phosphodiesterase Inhibitors; 13. Azulfidine and 5-Aminosalicylic Acid; 14. Histamine, Antihistamines, and the Immune Response; D) Drug therapy for AIDS: 15. Drug Therapy for AIDS; Part 3: Biologics:; A) Cytokines: 16. Hematopoietic Growth Factors; 17. Cytokines That Regulate Immune Inflamation: IL-4, IL-10 and IL-12; 18. The Interferons: Basic Biology and Therapeutic Potential; 19. Interleukin-2 Immunotherapy; 20. Interleukin-1 Receptor Antagonist; B) Macromolecules: 21. Intravenous Immunoglobin Therapy; 22. Immunoglobin A; 23. The Use of Recombinant, Soluble Forms of the Membrane Complement C3 Receptors, CR1 and CR2, as Inhibitors of Serum Complement Activation and Function; 24. Treatment of Angioedema due to C1 Inhibitor Deficiency; C) Antibody based therapies: 25. Production and Manipulation of Antibodies and T-Cell Receptors Using Recombinant DNA Technology; 26. Clinical Applications of Anti-Leukocyte Adhesion Molecule Monoclonal Antibodies; 27. Antibody Therapies of Drug Overdose; 28. Anti-Idiotype-Based Therapies; D) Immunotherapy of allergic disease: 29. Immunotherapy of Allergic Disease; E) Chimeric Proteins: 30. Immunotoxins; 31. Cytokine Toxin Fusion Proteins; 32. Immunoligands: CTLA4Ig and CD28 T Cell Costimulatory Pathway; F) Vaccines and Peptide-based therapy: 33. Bacterial Vaccines; 34. Oral Administration of Antigens; 35. Vaccine Therapy for AIDS; Part 4: Maneuvers:; A) Transplantation: 36. Therapeutic Approach to Organ Transplantation; 37. Renal Transplantation; 38. Pancreas Transplantation; 39. Cardiac Transplantation: Recipient Selection and Management; 40. Lung Transplantation; 41. Bone Marrow and Hemopoietic Stem Cell Transplantation; 42. Cell Transplantation; 43. Xenotransplantation; B) Cellular Therapy: 44. Cellular Therapy; 45. Stem Cell Therapy; 46. Cytokine Gene Transduced Tumor Vaccines; C) Gene therapy: 47. Gene Therapy for Inherited Immunodeficiences; D) Adjuvant Therapy: 48. Adjuvants; D) Extracorporeal Therapy: 49. Extracorporeal Photochemotherapy: A Cellular Therapy for Cutaneous T Cell Lymphoma, Selected Autoimmune Disorders and Organ Transplant Rejection; 50. Liver Transplantation; 51. Tolerogenic Peptides; 52. Plasmaphercis and Immunoadsorption